In the midst of escalating trade tensions and market volatility, European indices have experienced fluctuations, with the pan-European STOXX Europe 600 Index ending lower as central banks heighten their vigilance. In such uncertain times, stocks that combine growth potential with high insider ownership can offer a compelling investment narrative, as they may align management interests with shareholder value while navigating economic challenges.
Name | Insider Ownership | Earnings Growth |
Pharma Mar (BME:PHM) | 11.8% | 40.8% |
Vow (OB:VOW) | 13.1% | 111.2% |
Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
Elicera Therapeutics (OM:ELIC) | 20.5% | 97.2% |
Nordic Halibut (OB:NOHAL) | 29.8% | 60.7% |
CD Projekt (WSE:CDR) | 29.7% | 37.4% |
Xbrane Biopharma (OM:XBRANE) | 20% | 82.7% |
Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
Lokotech Group (OB:LOKO) | 13.9% | 58.1% |
Ortoma (OM:ORT B) | 27.7% | 68.6% |
Click here to see the full list of 217 stocks from our Fast Growing European Companies With High Insider Ownership screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Basic-Fit N.V., along with its subsidiaries, operates fitness clubs and has a market cap of approximately €1.23 billion.
Operations: The company's revenue segments include €522.10 million from Benelux and €693.10 million from France, Spain & Germany.
Insider Ownership: 12%
Revenue Growth Forecast: 11.3% p.a.
Basic-Fit has shown substantial growth, with earnings forecasted to grow significantly above the Dutch market average. It became profitable this year, reporting a net income of €8 million for 2024 compared to a loss previously. Despite its volatile share price and interest payments not well covered by earnings, Basic-Fit's revenue is growing faster than the market and its Return on Equity is expected to be high in three years. The company is considering a share repurchase program, potentially enhancing shareholder value.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vimian Group AB (publ) operates in the animal health industry globally, with a market capitalization of SEK20.22 billion.
Operations: Vimian Group AB generates revenue from its Medtech segment (€123.90 million), Diagnostics (€20.90 million), Specialty Pharma (€172 million), and Veterinary Services (€58.20 million).
Insider Ownership: 11.1%
Revenue Growth Forecast: 11.4% p.a.
Vimian Group's earnings are forecasted to grow significantly at 41.7% annually, outpacing the Swedish market. Insider activity has been positive, with substantial buying over the past three months and no significant selling. Despite trading below its fair value estimate, Vimian's revenue growth is slower than desired but still exceeds the Swedish market average. Recent inclusion in the OMX Nordic All-Share Index and proposed share class amendments reflect strategic developments aimed at future growth and shareholder engagement.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Init innovation in traffic systems SE, along with its subsidiaries, provides intelligent transportation systems solutions for public transportation globally and has a market cap of approximately €373.32 million.
Operations: The company's revenue is primarily derived from its Wireless Communications Equipment segment, totaling €265.67 million.
Insider Ownership: 39.6%
Revenue Growth Forecast: 14.7% p.a.
init innovation in traffic systems demonstrates potential as a growth company with high insider ownership, trading significantly below its estimated fair value. Despite a dividend yield of 2.12% not being well-covered by free cash flows, the company's earnings are forecast to grow at 25.39% annually, outpacing the German market. Recent financials show sales increased to €265.67 million from €210.8 million year-on-year, with net income rising slightly to €15.46 million, indicating steady progress amid strategic challenges.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ENXTAM:BFIT OM:VIMIAN and XTRA:IXX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.